A randomized controlled Alzheimer’s disease prevention trial’s evolution into an exposure trial: The preadvise trial
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
To summarize the ongoing Prevention of Alzheimer’s Disease (AD) by Vitamin E and Selenium (PREADViSE) trial as an ancillary study to SELECT (a large prostate cancer prevention trial) and to present the blinded results of the first year as an exposure study.
PREADViSE was designed as a double blind randomized controlled trial (RCT).
SELECT terminated after median of 5.5 years of exposure to supplements due to a futility analysis. Both trials then converted into an exposure study.
In the randomized component PREADViSE enrolled 7,547 men age 62 or older (60 if African American). Once the trial terminated 4,246 of these men volunteered for the exposure study. Demographics were similar for both groups with exposure volunteers having baseline mean age 67.3 ± 5.2 years, 15.3 ± 2.4 years of education, 9.8% African Americans, and 22.0% reporting a family history of dementia.
In the RCT men were randomly assigned to either daily doses of 400 IU of vitamin E or placebo and 200 µg of selenium or placebo using a 2×2 factorial structure.
In the RCT, participants completed the Memory Impairment Screen (MIS), and if they failed, underwent a longer screening (based on an expanded Consortium to Establish a Registry in AD [CERAD] battery). CERAD failure resulted in visits to their clinician for medical examination with records of these examinations forwarded to the PREADViSE center for further review. In the exposure study, men are contacted by telephone and complete the telephone version of the memory impairment screen (MIS-T) screen. If they fail the MIS-T, a Modified Telephone Interview of Cognitive Status (TICS-M) exam is given. A failed TICS-M exam also leads to a visit to their clinician for an in-depth examination and forwarding of records for a centralized consensus diagnosis by expert clinicians. A subgroup of the men who pass the MIS-T also take the TICS-M exam for validation purposes.
While this ancillary trial was open to all 427 SELECT clinical sites, only 130 (30.0%) of the sites chose to participate in PREADViSE. Staff turnover at the sites presented challenges when training persons unfamiliar with cognitive testing procedures to conduct the memory screens. In the RCT few participants (1.6%) failed the MIS screen and among those who passed this screen a significant practice effect was encountered. In the exposure study 3,581 men were reached by phone in year 1, 15.7% could not be reached after 5 calls, and of those contacted 6.0% refused the screen even after consenting to the procedures at their clinical site. Most notable is that the failure rate for the MIS-T increased fourfold to 7.2%. Of the 257 men who took the TICS-M, 84.0% failed and were asked to contact their physicians for a more detailed memory assessment, and approximately half of these had some form of dementia or cognitive impairment. Several of these dementia cases are not AD.
Partnering with SELECT led to an AD prevention trial conducted at a very reasonable cost by taking advantage of the experience and efficient clinical trial management found in a cancer cooperative group (Southwest Oncology Group or SWOG). Once unblinded, the RCT and exposure study data have the potential to yield new information on long term exposure to antioxidant supplements under controlled conditions.
- Vellas, B. Aisen, P.S., Sampaio, C., Carrillo, M, et. al. (2011). Prevention trials in Alzheimer’s disease: an EU-US task force report. Prog. Neurobiol., 95(4): 594–600. CrossRef
- Breitner, J.C. Baker, L.D., Montine T.J., Meinert, C.L., Lyketsos C.G. et al. (2011). Extended results of the Alzheimer’s disease anti-inflammatory prevention trial. Alzheimers Dement. 7(4): 402–411 CrossRef
- Espeland MA, Rapp SR, Shumaker SA, Brunner R, et al. (2004) Conjugated equine estrogens and global cognitive function in postmenopausal women: Women’s Health Initiative Memory Study. J.A.M.A. 291(24): 2959–2968. CrossRef
- Shumaker SA, Legault C, Kuller L, Rapp SR, et al. (2004) Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study. J.A.M.A. 291(24): 2947–2958. CrossRef
- Snitz, B.E., O’Meara, E.S., Carlson, M.C., Arnold, A.M. et. al. (2009) Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. J.A.M.A., 302(24): 2663–2670. CrossRef
- Dekosky ST, Williamson JD, Fitzpatrick AL, Ives DG, et al. (2008) Ginkgo biloba for prevention of dementia: a randomized controlled trial. J.A.M.A. 300(19): 2253–2262. CrossRef
- Goss-Sampson, M.A., MacEvilly, C.J., Muller, D.P.R. (1988) Longitudinal studies of the neurobiology of vitamin E and other antioxidant systems, and neurological function in the vitamin E deficient rat. J. Neurol. Sci. 87, 25–35. CrossRef
- Pillai, S.R., Traber, M.G., Steiss, J.E., Kayden, H.J., Cox, N.R. (1993) Alpha-Tocopherol concentration of the nervous system and selected tissues of adult dogs fed three levels of vitamin E. Lipids 28, 1101–1105. CrossRef
- Sano, M., Ernesto, C., Thomas, R.G., Klauber, M.R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C.W., Pfeiffer, E., Schneider, L.S., and Thal, L.J. (1997) A controlled trial of selegiline, alpha-tocopherol, or both as a treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. N. Engl. J. Med. 336, 1216–1222. CrossRef
- Markesbery, W.R., Lovell, M.A. (1998) Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer’s disease. Neurobiol. Aging 19, 33–36. CrossRef
- Markesbery, W.R., Carney, J.M. (1999) Oxidative alterations in Alzheimer’s disease. Brain Pathol. 9, 133–146. CrossRef
- Lippman, S.M., Klein, E.A., Goodman, P.J., et. al. (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer prevention Trial (SELECT). J.A.M.A., 301(1): 39–51. CrossRef
- Klein, E.A., Thompson Jr. I.M., Tangen, C. M., Crowley, J.J. et al. (2011). Vitamin E and the risk of prostate cancer: the selenium and vitamin E cancer prevention trial (SELECT). J.A.M.A., 306(14): 1549–1556. CrossRef
- Klein EA, Thompson IM, Lippman SM, et al. (2000) SELECT: the Selenium and Vitamin E Cancer prevention Trial: rationale and design. Prostate Cancer Prostatic Dis. 3(3): 145–151. CrossRef
- Caban-Holt, A., Schmitt, F.A., Runyons, C.R., Kryscio, R.J., Mendiondo, M.S., Sundquist, M.S., Markesbery, W.R., Coltman, C.A., Crowley, J.J., Goodman, P., & Hartline, J.A. (2006). Studying the effects of vitamin E and Selenium for Alzheimer’s disease prevention: the PREADVISE model. In: Vellas B, Fitten L, Winblad B, Feldman H, Grundman M, Giacobini E, Kurz A (eds). Research and Practice in Alzheimer’s Disease: Volume 11 (pp. 124–130). Paris: Serdi Publisher.
- Buschke, H., Kulansky, G., Katz, M., Stewart, W.F., Sliwinski, M.J., Eckholdt, H.M., & Lipton, R.B. (1999). Screening for dementia with the Memory Impairment Screen. Neurology, 52, 231–238. CrossRef
- Morris, J.C., Heyman, R.C., Mohs, J.P., Hughes, B.G. et. al. (1989) The Consortium to establish a registry for Alzheimer’s disease (CERAD). Part 1. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology 39: 1159–1165. CrossRef
- Welsh KA, Butters N, Mohs RC, Beekly D, Edland S, Fillenbaum G, Heyman A. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology. 1994 Apr;44(4):609–614. CrossRef
- Lipton, R.B., Katz, M.J., Kuslansky, G., Sliwinski, M.J., Stewart, W.F., Verghese, J., Crystal, H.A., Buschke, H. (2003). Screening for dementia by telephone using the memory impairment screen. J. Am. Geriatr. Soc., 51(10): 1382–1390. CrossRef
- Brandt, J., Spencer, M., Folstein, M. (1988). The telephone interview for cognitive status. Neuropsychiatry, Neuropsychology & Behavioral Neurology 1: 111–117.
- Plassman BL, Welsh KA, Helms M, Brandt J, Page WF, Breitner JC. Intelligence and education as predictors of cognitive state in late life: a 50-year follow-up. Neurology. 1995 Aug;45(8):1446–1450. CrossRef
- Welsh, K.A., Breitner, J.C.S., Magruder-Habbib, K.M. (1993) Detection of dementia in the elderly using telephone screening of cognitive status. Neuropsychiatry, Neuropsychology & Behavioral Neurology, 1: 103–111.
- Galvin JE, Fagan AM, Holtzman DM, Mintun MA, Morris JC. Relationship of dementia screening tests with biomarkers of Alzheimer’s disease. Brain. 2010 Nov;133(11):3290–3300.
- Yesavage, J. A., Brink, T. L., Rose, T. L., Lum, O., Huang, V. S., et al. (1983). Development and validation of a geriatric depression screening scale: A preliminary report. Journal of Psychiatric Research, 17, 37–39. CrossRef
- Kryscio, R.J., Mendiondo, M.S., Schmitt, F.A., Markesbery, W.R. (2004). Designing a large prevention trial: statistical issues. Stat. Med., 23(2): 285–296. CrossRef
- Stern Y, Gurland B, Tatemichi TK, Tang MX, Wilder D., Mayeaux R. (1994) Influence of education and occupation on the incidence of Alzheimer’s disease. J.A.M.A. 271(13): 1004–1010. CrossRef
- Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Metaanalysis: High dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2004; 142:37–46.
- Berry D, Wathen JK, Newell M. Bayesian model averaging in meta-analysis: vitamin E supplementation and mortality. Clinical Trials 2009; 6:28–41. CrossRef
- Abner EL, Schmitt FA, Mendiondo MS, Marcum JL, Kryscio RJ (2011) Vitamin E and All-cause mortality: a meta-analysis. Current Aging Science 4(2): 158–170. CrossRef
- A randomized controlled Alzheimer’s disease prevention trial’s evolution into an exposure trial: The preadvise trial
The journal of nutrition, health & aging
Volume 17, Issue 1 , pp 72-75
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Alzheimer’s disease
- telephone screening
- cognitive assessments
- case ascertainment
- Industry Sectors
- Author Affiliations
- 1. University of Kentucky Sanders-Brown Center on Aging, Lexington, KY, USA
- 2. Department of Biostatistics, University of Kentucky Sanders-Brown Center on Aging, Lexington, KY, USA
- 3. Department of Statistics, University of Kentucky Sanders-Brown Center on Aging, Lexington, KY, USA
- 4. Department of Neurology, University of Kentucky Sanders-Brown Center on Aging, Lexington, KY, USA
- 5. Department of Psychiatry & Psychology, University of Kentucky Sanders-Brown Center on Aging, Lexington, KY, USA
- 6. Department of Behavioral Sciences, University of Kentucky Sanders-Brown Center on Aging, Lexington, KY, USA
- 7. Cancer Research and Biostatistics/SWOG Statistical Center, Seattle, WA, USA
- 8. Cleveland Clinic, Cleveland, OH, USA